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The purpose of this study was to explore the incidence of late relapse in patients with malignant germ cell tumour (MGCT) in a
population-based series, with emphasis on the mode of detection, survival, and the relevance of histological findings. The clinical
records from a population-based cohort of patients with seminoma (n¼1123) or non-seminoma (n¼826) were evaluated for late
relapses. Twenty-five patients developed a late relapse. The cumulative 10-year incidence rate was 1.3%. All 10 seminoma patients,
but only eight of 15 non-seminoma patients relapsed with vital malignant tumour (P¼0.02). Teratoma or necrosis was found in
seven of nine primarily chemotherapy-treated non-seminoma patients with normal tumour markers at late relapse. Six of nine
patients operated with limited retroperitoneal lymph node dissection as part of the primary treatment had relapsed retroperitoneally
outside the original operation field. The 10-year cause-specific survival was 68% in all patients, 50% in patients relapsing with vital
malignant tumour and 100% in those with teratoma/ necrosis before or after salvage chemotherapy. The 10-year incidence rate of
late relapses of 1.3% might reflect the true incidence rate in a population-based cohort of MGCT patients, with cure in at least half of
them.
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Late relapses of malignant germ cell tumours (MGCTs) are rare
events. Most investigators define late relapses as recurrence at least
2 years after completion of successful primary treatment and
differentiate between those occurring before and after 5 years
(Baniel et al, 1995; Gerl et al, 1997; Shahidi et al, 2002; George et al,
2003; Dieckmann et al, 2005). Due to the rarity of late relapses,
systematic reports on this topic are restricted to large referral-
centres, and may therefore be comprised of late relapsing patients
who have received their primary treatment elsewhere in addition
to those who have had their primary treatment at the respective
institution. Reported cure rates in patients with these often highly
aggressive and chemotherapy-resistant tumours vary from 26 to
69% (Borge et al, 1988; Baniel et al, 1995; Gerl et al, 1997; Shahidi
et al, 2002; George et al, 2003; Lipphardt and Albers, 2004;
Dieckmann et al, 2005). In 1988, Borge et al (1988) from our
hospital reported a crude late relapse rate of 1.5%, which is lower
than that observed by most other investigators (Baniel et al, 1995;
Gerl et al, 1997; Shahidi et al, 2002; George et al, 2003).
Some authors recommend regular follow-up of all patients with
MGCT beyond the usual 5-year period, arguing that asymptomatic
patients with early-detected relapses have a better prognosis
compared to patients with symptoms (Gerl et al, 1997; George
et al, 2003). However, regular follow-up of all patients with MGCT
at specialist centres beyond 5 years might represent an unneces-
sary routine in the majority of men.
The purpose of the present study is to explore the true incidence
rate, mode of detection, and outcome of late relapsing MGCT
patients in a large population-based cohort of patients who had
their primary treatment at the Norwegian Radium Hospital (NRH).
We aim to examine the impact of the histology both at initial
diagnosis and at late relapse on clinical course and outcome.
PATIENTS AND METHODS
Patients
Since 1970 post-orchiectomy treatment was performed at the NRH
in all patients with a germ cell malignancy in the southern part of
Norway. Roughly, half of Norway’s MGCT diagnoses are made in
the population from this geographic area. At referral, sections from
the orchiectomy specimen are routinely reviewed. In order to
assess the risk of late relapses after modern treatment of MGCT, all
seminoma-patients referred to the hospital from January 1971 to
December 1997, and all non-seminoma-patients referred from
January 1980 (after the advent of cisplatin) to December 1997, were
screened for late relapse, based on the hospital’s patient registry.
The registry separates patients with testicular cancer (TC) from
those with extragonadal germ cell tumour (EGGCT) from 1980
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sonwards. Patients with TC or EGGCT were eligible for the present
analysis if they: (1) had been considered tumour-free after their
primary treatment at the NRH; and (2) had remained relapse-free
for at least 30 months after the initial diagnosis (assuming
a maximal treatment period of 6 months), but had developed
a relapse thereafter. The event of a contra-lateral TC was not
counted as a late relapse.
Staging
Extragonadal germ cell tumours were not staged, but described as
mediastinal or retroperitoneal primaries. For the purpose of the
present study, patients with metastases were staged retrospectively
according to the International Germ Cell Consensus Classification
Group (IGCCCG) (1997) and the UICC-staging guidelines (Sobin
and Wittekind, 2002).
Treatment
The treatment strategies have been described previously (Fossa
and Ous, 1985; Fossa et al, 2003) and are summarised in Table 1.
Treatment for patients with seminoma had remained principally
unchanged from 1971 to 1997. Radiotherapy was given in stage I
and small volume stage II disease and chemotherapy was given for
advanced seminoma, followed by post-chemotherapy radiotherapy
up until 1987. Before 1980, chemotherapy consisted of alkylating
agents. After 1980, cisplatin-based chemotherapy was used.
The advent of cisplatin-based chemotherapy at the end of
the 1970s represented a major change in the treatment of non-
seminoma patients. Up to 1990, unilateral template RPLND
(retroperitoneal lymph node dissection) was used in stage I or
small volume stage II disease (Fossa and Ous, 1985). From 1990 a
surveillance policy for stage I was established. In metastatic
patients, post-chemotherapy RPLND was initially performed
bilaterally (Whitmore Jr, 1979). From 1986, ipsilateral unilateral
template RPLND only was introduced, refined by nerve-sparing
techniques, whenever possible, after 1990 (Donohue et al, 1990;
Jacobsen et al, 1999).
Follow-up
Patients, rendered tumour-free by primary treatment, were with
increasing intervals followed for 5 years at the hospital’s out-
patient department with clinical-, radiological-, and biochemical
examinations. Computed tomography (CT)-examinations were
introduced in the 1980s and were performed predominantly during
the first 2 years in patients following a surveillance policy or after
treatment for advanced stages. Generally, no further follow-up was
carried out beyond 5 years at the oncology centre, except in
patients who were ad hoc considered risk patients. All patients
with relapses were referred to our hospital for treatment.
Clinical course
Date of initial diagnosis and of relapse, IGCCCG-stage (1997),
UICC-stage (Sobin and Wittekind, 2002), tumour localisation at
the time of relapse, date of start and type of primary and relapse
treatment, and serum tumour markers before initial treatment and
at time of relapse were retrieved from medical records. The mode
of relapse detection was also noted (coincidental finding at routine
follow-up or due to clinical symptoms). From 1985 onwards, a
histological confirmation of the late relapse prior to salvage
treatment was attempted. All available histological specimens were
reviewed by one pathologist (GCA) and described according to the
WHO classification system (Ulbright Thomas et al, 1999). At
relapse the diagnosis of viable malignant tumour, that is, non-
teratomous- and non-necrotic tumours, was based on histology
or on AFP/HCG elevation. Patients with late relapses were treated
on an individual basis at the responsible physician’s discretion.
Chemotherapy for relapses consisted principally of cisplatin-based
combinations, preferentially using drugs that had not been
employed previously in the respective patient.
Statistics
The SPSS program version 12.0.2 was used for descriptive (median,
range) and analytical methods (t-test, Mann–Whitney, w
2, Fisher’s
Exact, and Kaplan–Meier procedure and log-rank test for survival
analysis). All patients were followed to date of death or, for
surviving patients, to the cutoff date of the study (October 1st
2004). The incidence-observation time ranged from date of initial
diagnosis of MGCT to date of late relapse diagnosis, patient’s death
or cutoff date, whichever came first. Survival-observation time
ranged from date of late relapse diagnosis to patient’s death
or cutoff date. A P-value o0.05 was considered statistically
significant.
Table 1 Treatment strategies
Period Stadium I and II (small volume)
a Stadium II (high-volume)
b, III and IV
Seminoma 1971–1997 Infradiaphragmal radiotherapy Chemotherapy
Alkylating agentso1980
Cisplatin-based41980
Followed by
Radiotherapy or surgeryo1988
Non-seminoma 1980–1989 Primary RPLND (retroperitoneal lymph node
dissection) (unilateral template)+Cisplatin-
based chemotherapy in case of metastases
Induction chemotherapy, followed by surgical removal of residual
masses: bilateral template RPLNDo1985, unilateral RPLND, if
possible41985
(borders for unilateral template: aortic midline,
ipsilateral ureter, renal vein, bifurcation of the
ipsilateral iliac artery)
(borders for bilateral RPLND: ureters, the renal veins and the
ipsilateral iliac bifurcation)
1990–1997 Stage I: low risk
c: wait and see, high risk
d:
adjuvant chemotherapy
Stage II (all)–IV chemotherapy, followed by surgical removal of all
residual masses, even in case of ‘normal’ abdominal CT, by nerve-
sparing RPLND, if possible
EGGCT 1980–1997 Cisplatin-based chemotherapy, followed by surgical removal of residual masses, exceptionally radiotherapy only in a single
small seminomatous mass
ao3cm.
bX3cm.
cNo vascular invasion, orchiectomy specimen.
dVascular invasion, orchiectomy specimen.
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Patients and incidence of late relapses
One thousand one hundred and twenty-three patients with
seminoma and 826 patients with non-seminoma had their primary
treatment at the NRH from 1971 and 1980, respectively, until
December 1997. Twenty-five (1.3%, seminoma: 10, non-seminoma:
15) of these 1949 patients developed a late relapse (TC: 21, EGGCT:
4, Table 2). Their pre-relapse treatment consisted of platinum-
based chemotherapy (seminoma: 3; non-seminoma: 14) or radio-
therapy only (seminoma: 7). One patient following the surveillance
policy.
The cumulative 10-year incidence rate of all 25 late relapses was
1.3% (95% CI: 0.8–1.8, after 20 years 1.4%, 95% CI: 0.9–2.0,
Figure 1). All but two relapses were diagnosed within the first
decade after the initial diagnosis of MGCT (Figure 1). The 10-year
cumulative incidence rate for seminoma patients was 0.8% (95%
CI: 0.2–1.3) and 1.9% (95% CI: 0.9–2.8) for non-seminoma
patients (log-rank test, P¼0.047). The 10-year incidence-rate of
patients diagnosed in 1980 or later was 1.2% (95% CI: 0.6–1.7) for
1570 TC patients, and 6.0% (95% CI: 0.0–12.5) for 60 patients with
EGGCT (log-rank test Po0.001). In patients who received primary
chemotherapy (n¼480), the cumulative 10-year incidence rate was
3.1% (95% CI: 1.4–4.8%). This was significantly higher than the
comparable incidence rate of 0.7% in the remaining patients
(n¼1469) who did not receive primary chemotherapy (95% CI:
0.3–1.1%, log-rank test, Po0.001). Fifteen patients developed a
recurrence more than 66 months after orchiectomy, that is, very
late relapses. Their clinical parameters or survival did not differ
from the others.
Mode of detection and presentation of late relapses
Eleven patients were diagnosed symptom-free during scheduled
routine follow-up examinations in 10 or during an assessment of
long-term TC-survivors in one (#8, Table 3) (Fossa et al, 2003).
Symptomatic patients presented later and with bigger masses
compared to the former group (n¼14, Mann–Whitney, P¼0.013
and 0.025, respectively). Relapse was diagnosed by routine CT-
examination in only one asymptomatic patient, whereas the other
relapses were diagnosed by low-cost procedures like palpation,
blood tests or chest X-ray. No significant differences in age at
initial diagnosis, stage or histology were seen between the two
groups.
Initial seminoma
All, except one patient (#6) presented with extra-lymphatic
metastases at late relapse (Table 3). All 10 seminoma patients
relapsed with viable MGCT. In eight patients pre-salvage treatment
histology was available, which was separate from seminoma in
three.
Table 2 Demographics in 25 patients with late relapses of MGCT, by
mode of detection
All Symptoms Routine
n (%) 25 (100) 14 (56) 11 (44)
Age
a (years) 30 (20–68) 27 (20–48) 36 (23–68)
Primary histology
Seminoma 10 6 4
Non-seminoma 15 8 7
UICC stage
b
I 321
I S 211
I I 642
III 10 6 4
Extragonadal 4 1 3
IGCCCG
c category stage
Good 11 7 3
Intermediate 5 2 4
Poor 3 1 2
Chemotherapy in primary treatment
Seminoma 3 1 2
Nonseminoma 14 7 7
Months to relapse
a 55 (32–224) 88 (40–224) 41 (32–110)
Sites of relapse
Retroperitoneal 9 6 3
Mediastinum 6 3 3
Lung/pleura 5 2 3
Neck/supraclavicular 3 1 2
Retrocrural 1 1
Pelvis 3 2 1
Number of relapse sites 27
d 15
d 12
d
Symptoms leading to unscheduled visit
Tiredness 4
Pain (back/abdominal) 6 (3/3)
Dyspnoea 2
Peripheral oedema 1
Dysphagia 1
Findings at routine follow-up leading to diagnosis
Radiology (chest X-ray/CT-thorax) 4 (3/1)
Elevated markers (AFP/HCG) 4 (2/2)
Palpable masses (supraclv./pelvis) 3 (2/1)
Diameter (mm)
a 35 (10–135) 43 (11–135) 20 (10–46)
Status
NED
e 16 10 6
DOD
e 734
DID
e 211
aMedian (range).
bInternational Union against cancer (Sobin and Wittekind, 2002).
cInternational Germ Cell Consensus Classification Group (1997).
dThree patients
experienced the late relapse at two sites, as shown in Tables 2 and 3.
eStatus: NED
alive, no evidence of disease; DOD, dead of disease (MGCT); DID, dead of
intercurrent disease, tumour-free.
Non-seminoma, n =15
All
Seminoma, n =10
2.0
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1.0
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Figure 1 Cumulative late relapse incidence in 1949 MGCT patients.
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The lungs were the only site of late relapse in three patients, all of
which had had supra-diaphragmal disease at initial presentation
(Table 4). In one patient (#18), the lungs and retroperitoneal
lymph nodes were affected. All others had lymph node metastases
only. Three of four TC patients with no primary RPLND relapsed
retroperitoneally, including the surveillance patient (#11, #12, #18).
Of nine TC patients with primary postchemotherapy RPLND, six
presented with retroperitoneal relapses, all located close to, but
outside the operation field (Figure 2).
Of nine patients with initial chemotherapy and normal tumour
markers, seven relapsed with teratoma (n¼6) or necrosis (#14)
and two with viable malignant tumour. The presence of viable
malignant tumour was more frequent in initial seminoma- than in
initial non-seminoma patients (10 out of 10, eight out of 15,
Fisher’s Exact, P¼0.02).
Treatment
All 10 seminoma patients and seven of the eight non-seminoma
patients with viable malignant tumours received salvage chemo-
therapy. Eight of the 10 tumour-marker-negative non-seminoma
patients underwent surgery alone, whereas the remaining two
(#11, #22) received subsequent chemotherapy. Chemotherapy
represented the initial step of salvage treatment in four of five
non-seminoma patients with elevated HCG/AFP. The fifth patient
(#8) underwent surgery, despite elevated serum HCG. The
rationale behind was a spontaneous drop in serum HCG before
any therapeutic intervention, suggesting intermittent leakage
from a cystic teratoma (van der Gaast et al, 1991; Ustun et al,
2002).
Eight patients did not undergo surgery for their late relapse.
Seven out of these had initial seminoma and received a combi-
nation of chemotherapy and radiotherapy. The remaining one
patient (#25), with local recurrent primary abdominal EGGCT, was
the only one in our series who was solely treated by chemotherapy.
There was no significant difference in survival between these
eight patients and the remaining 17 who underwent surgery as part
of relapse treatment (log-rank, P¼0.24). Eleven of the operated
patients had teratoma or necrosis and were rendered tumour-free
by surgery alone. Of the remaining six with viable malignant
tumour, three (#8, #11 and #24) could be operated radically. A
radical operation was not feasible in the other three cases (#15, #16
and #22).
Outcome and survival
Twenty-two out of 25 patients (88%) were considered tumour-free
after treatment of the first late relapse. Seven patients experienced
a second relapse, four of them with viable malignant tumour
(#1, #10, #22 and #25).
After a median observation-time of 74 months (range: 17–241
months), 16 patients were alive without MGCT and seven patients
were dead of their malignancy. Thus, the 10-year postrelapse
cause-specific survival was 68 % (95% CI: 48–88%, Figure 3).
Teratoma or necrosis at late relapse (before or after salvage
chemotherapy, n¼11) conferred a 100% cause-specific survival,
compared to a 50% cause-specific survival in the remaining 14
patients with viable malignant tumour (95% CI: 14–79%, log-rank
test, P¼0.009, Figure 3). The former 11 patients with favourable
histology could all be operated radically, whereas all three with
incomplete resection had viable malignant tumour and died within
2 years (#15, #16, #22).
Factors without statistical significance for survival were: the
presence of symptoms at late relapse (P¼0.65), initial seminoma
vs non-seminoma (P¼0.99), UICC-stage (P¼0.80), IGCCCG-
prognosis-group (P¼0.67), chemotherapy-naivety at late relapse
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s(P¼0.83), initial presence of teratoma (P¼0.91), and the
integration of surgery into the treatment of late relapse (P¼0.24).
DISCUSSION
In this large population-based series of 1949 patients with MGCT,
only 25 patients (1.3%) with relapses were identified. All 10
seminoma and eight of 15 non-seminoma patients relapsed with
viable malignant tumour. The cause-specific postrelapse 10-year
survival was 68% in all patients, 50% in patients with vital
malignant tumour at late relapse and 100% in patients with
teratoma or necrosis before or after salvage chemotherapy. Initial
histology or the presence of symptoms was of no prognostic
importance.
Our incidence rate of 1.3% is considerably lower than figures
from the literature (2.9% (Baniel et al, 1995), 4.3% (Gerl et al,
1997), 5.9% (Shahidi et al, 2002)). These discrepancies may be due
to referral and publication bias in that patients with poor
prognosis, and thus, at high risk of late relapses, may preferably
have been referred to experienced centers (Aass et al, 1991; Collette
et al, 1999), which regularly publish their results. A referral-bias
may also explain the finding of 40% initial seminoma in late
relapses compared to 2–4% in the series from the Indiana group
(Baniel et al, 1995; George et al, 2003), 4% in a German series (Gerl
et al, 1997), or to 28% in a series from the Royal Marsden Hospital
(Shahidi et al, 2002). The latter series was comprised solely of
patients who had their primary treatment at the respective
hospital. Referral-bias is excluded when the incidence of late
relapse is calculated in population-based cohorts, as in the present
series.
At our institution, postchemotherapy RPLND is performed
routinely in all patients who initially present with retroperitoneal
lymph node metastases, including cases of minimally residual
disease (Fossa et al, 1989, 1992; Oldenburg et al, 2003). This
aggressive surgical approach as part of primary treatment may to
some extent explain the low risk of late relapses in our patient
population. Stephenson and Sheinfeld support this view by their
review on the impact of RPLND in the management of TC,
which shows that relapses after primary RPLND in stage I/II
non-seminomas are rather rare, cisplatin-sensitive, and extra-
retroperitoneal versus more frequent and predominantly retro-
peritoneal, cisplatin-resistant relapses after primary chemotherapy
alone (Stephenson and Sheinfeld, 2004).
Strategies to minimise the retroperitoneal operation field
by limited and nerve-sparing RPLND may have increased the
risk of relapses. Six of nine patients relapsed retroperitoneally
after introduction of this strategy. Although we do not have a
control group to compare with, it seems prudent to assume that
some of these relapses may have been avoided by more extensive
surgical approaches in the first place. However, a principal change
from the ‘nerve sparing’ procedure would imply a major increase
in side effects like retrograde ejaculation (Jacobsen et al, 1999).
Four of 10 initial seminoma patients relapsed as non-seminoma,
one non-seminoma patient relapsed as seminoma, and three
relapses comprised undifferentiated carcinoma, which may
represent somatic transformation in teratomas. Thus, the initial
histology is an unreliable predictor of the late relapse histology.
However, the histological diagnosis of late MGCT in late relapses
may be difficult, as evident in our cases #24 and #25, in whom
the diagnoses were revised from adenocarcinoma to yolk-sac
tumour (confer Appendix A). One of the yolk-sac tumours was of
the parietal type, a probably chemotherapy-induced feature
(Damjanov et al, 1984; Michael et al, 2000).
Before applying salvage chemotherapy in patients considered to
have a late MGCT relapse, we strongly recommend to verify the
assumed diagnosis histologically by a large, representative biopsy
or, if feasible, by the completely removed lesion (Nichols, 1999).
The latter approach led to cure in eight of our non-seminoma
patients. AFP/HCG elevation in patients strongly suggests
the presence of MGCT, and cisplatin-based chemotherapy
may be given first, followed by a complete resection of residual
masses, if necessary, by multiple advanced surgical proce-
dures (Murphy et al, 1993). Nevertheless, a presalvage chemo-
therapy biopsy may prove invaluable even in patients with elevated
serum tumour markers, since HCG or AFP elevation may occur
unrelated to MGCT. Furthermore, one might consider omitting
post-chemotherapy surgery in case of pure seminoma in the late
relapse.
A survival benefit of asymptomatic patients with late relapses as
reported by George et al (2003) could not be confirmed. Some
investigators advocate regular life-long follow-up of all patients
with MGCT (Baniel et al, 1995; Gerl et al, 1997; George et al, 2003).
However, clinicians from the Royal Marsden Hospital consider a
Lung/pleura: #14,
Neck: #13,
Mediastinum: #21
3
6
I supradiaphragmal relapses
II infradiaphragmal relapses
Late relapse localisation: Contralateral Retrocrural Pelvic Pelvic Retropancreatic Adrenal gland/hypochondrium
#17 #23 #19 #20 #16 #22
Same site Retrocrural Mediastinum 2nd relapse localisation:
Figure 2 Late relapse sites of nine non-seminoma TC patients after post-chemotherapy RPLND. Sketches show operation-fields/templates in light grey
and site of first relapse in dark grey.
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sTable 4 Clinical and histopathological parameters in 15 patients with initial non-seminoma and late relapse
Primary presentation Interval Relapse features
IGCCCG # Year
UICC-
stage Histology Treatment
Residual
mass
histology
Detection
mode Months Site Size (mm)
AFPm/
HCGm
Histology
chemoth
naive Treatment
Histology
chemoth
exposed
Outcome
(obs-time)
Good 11 1995 I T, S, YS Surveillance s-back-pain 40 rtrpt 45 n Sem rplnd-r, 3 BEP NED (74)
12 1992 IS EC, YS CEB s-tiredness 116 rtrpt 75 n T rplnd-r NED (34)
13 1993 II EC BEP, rplnd-r r-palpation 43 Neck 20 n T lr 2nd relapse
Features of 2nd relapse after late relapse 20 rcrl 37 n T lr NED-r (95)
14 1982 III EC, CC CVB, rplnd-b Necr s-tiredness 103 Lung/pleura 11 n Necr lr NED (162)
15 1981 III Sem
a CVB, 40Gy r-chestXray 67 Lung/pleura 35 AFP (22) 3EP, 48Gy, lr YS DOD (23)
16 1980 III EC, T CVB, BEP,
rplnd-b,
4CAOS, th-
tomy
T, T s-abd.pain 100 rtrpt 115 AFP (10460) 2BEP; rplnd-
b, 2VIP
YS DOD (17)
17 1997 II EC, YS, T BEP, rplnd-l T s-abd.pain 53 rtrpt 30 n T rplnd-r NED (39)
Intermediate 18 1991 IS EC, YS CEB r-marker 38 lung+rtrpt 27 AFP (22) 3BEP, rplnd-b T NED (125)
19 1993 II T, YS, EC BEP, rplnd-b T r-abdCT 39 pelvis 46 n T plnd 2nd relapse
Features of 2nd relapse after late relapse 27 rcrl 37 n T rplnd NED-r (101
20 1992 III PS, EC, T BEP, rplnd-b T s-abd.pain 113 pelvis-b 40 n T plnd-b NED (35)
21 1984 III EC, YS, T, S CVB, rplnd-b T r-marker 36 Mediast 45 HCG (3052) 4BEP, lr T NED (215)
22 1993 III S, T, EC BEP, rplnd-b;
VIP
CC s-back-pain 90 rtrpt+rcrl 125 n Ca lr, 3TC 2nd relapse
Features of 2nd relapse after late relapse 3 rtrpt 94 n lr Ca DOD-r (17)
Poor 23 1989 III S, EC, YS,
CC, T
BopVip,
rplnd-b
T s-back-pain 51 rcrl 17 n T lr 2nd relapse
Features of 2nd relapse after late relapse 10 Mediast 28 n T lr NED-r (149)
24 1993 mediast YS BEP, th-tomy Necr r-chestXray 69 Lung/pleura 15 n YS lr NED (65)
25 1980 abd EC BEP, EP,
rplnd-b
T r-marker 49 rtrpt 20 AFP (33) EP, BOP/VIP 2nd relapse
Features of 2nd relapse after late relapse 32 Lung/pleura 32 AFP (25) BOP/VIP,
40Gy
DOD-r (87)
Abbreviations: IGCCCG, International Germ Cell Consensus Classification Group; AFP (), alpha-fetoprotein (ng/ml); HCG (), human choriogonadotropin (iU/l); obs-time, observation time in months after treatment of late relapse.
Histology: Ca, Carcinoma not further specifiable; CC, chorio-carcinoma; EC, embryonal carcinoma; Necr, necrosis; Sem, seminoma; T, teratoma; YS, yolk sac-tumour. Chemotherapy regimens: BEP, bleomycin, etoposide, cisplatin, CEB,
carboplatin, etoposide, bleomycin; CVB; cisplatin, vinblastine, bleomycin; EP, etoposide, cisplatin; VIP, etopside, Ifosfamide, cisplatin; CAOS (cyclophosphamide, actinomycin-D, oncovin, sendoxan); TC (taxol, carboplatin). Outcome:
DOD, dead of disease; DID, dead of intercurrent disease; NED, no evidence of disease. Others: Gy, radiotherapy dose in Gray; rtrtp, retroperitoneum; lr, local resection; rplnd-r-l-b, retroperitoneal lymph node dissection-right
template, -left template, bilateral, respectively.
aPure seminomatous histology, non-consideration of elevated AFP before its routine use in our hospital resulted in misclassification as seminoma.
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Clinical Studies5-year follow-up sufficient in TC patients except in those
presenting with metastatic non-seminoma (Shahidi et al, 2002).
A German multicentre study recommends 10-year follow-up risk
of risk patients, for example, those with previous relapse, teratoma,
or chemotherapy-requiring metastases (Dieckmann et al, 2005).
We consider the latter approach as reasonable, since relapses after
10 years were very rare. Two patients from the present series (#16
and #22) might have especially benefited from such extended
follow-up as their lesions probably have advanced uninhibited
over years until symptoms coincided with inoperability. It seems
that primary chemotherapy-requiring patients and those with
EGGCT were at particularly high risk for late relapses. These
should be considered for prolonged, at least 10-years, follow-up.
Thereafter, annual routine check-ups may be arranged in
conjunction with general practitioners with regard to late relapses,
second cancers, and treatment-induced metabolic changes
(Vaughn et al, 2002; Sagstuen et al, 2005; Travis et al, 2005).
The 10-year cause-specific survival rate of 68% for our 25
patients is promising when compared to most other reports
(Baniel et al, 1995; Gerl et al, 1997; George et al, 2003). Except for
the small number of patients, a possible explanation for the
favourable survival-rate may be that our series is comprised of all
patients with late relapses, both those recurring after initially
advanced stages and those with stage I, and includes both initial
seminoma and non-seminoma patients.
In summary, the low incidence-rate of 1.3% is probably best
explained by the population-based approach of all patients with
MGCT, treated at one experienced oncological unit, and by the
aggressive treatment of the initial MGCT. All 10 seminoma
patients, but only eight of 15 non-seminoma patients, relapsed
with viable malignant tumour. The 10-year survival rate in all
patients was 68%, 100% in those with teratoma/necrosis, and 50%
in those with vital malignant tumours.
REFERENCES
Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B,
Baldetorp L, Ahlstrom S, Fossa SD (1991) Prognostic factors in
unselected patients with nonseminomatous metastatic testicular cancer:
a multicenter experience. J Clin Oncol 9: 818–826
Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995)
Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176
Borge N, Fossa SD, Ous S, Stenwig AE, Lien HH (1988) Late recurrence of
testicular cancer. J Clin Oncol 6: 1248–1253
Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de
Mulder PH, Neymark N, Lallemand E, Kaye SB (1999) Impact of the
treating institution on survival of patients with ‘poor-prognosis’
metastatic nonseminoma. European Organization for Research and
Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group
and the Medical Research Council Testicular Cancer Working Party.
J Natl Cancer Inst 91: 839–846
Damjanov I, Amenta PS, Zarghami F (1984) Transformation of an Afp-
positive yolk-sac carcinoma into an Afp-negative neoplasm – evidence
for in vivo cloning of the human parietal yolk-sac carcinoma. Cancer 53:
1902–1907
Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O,
Mullerleile U, Kuczyk M (2005) Late relapse of testicular germ cell
neoplasms: a descriptive analysis of 122 cases. J Urol 173: 824–829
Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G, Jewett MAS
(1990) Nerve-sparing retroperitoneal lymphadenectomy with preserva-
tion of ejaculation. J Urol 144: 287–292
Fossa SD, Dahl AA, Loge JH (2003) Fatigue, anxiety, and depression in
long-term survivors of testicular cancer. J Clin Oncol 21: 1249–1254
Fossa SD, Ous S (1985) Primary unilateral retroperitoneal lymph node
dissection [RLND] in non-seminomatous testicular cancer. Prog Clin
Biol Res 203: 319
Fossa SD, Ous S, Lien HH, Stenwig AE (1989) Post-chemotherapy lymph
node histology in radiologically normal patients with metastatic
nonseminomatous testicular cancer. J Urol 141: 557–559
Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE (1992) Is
postchemotherapy retroperitoneal surgery necessary in patients with
nonseminomatous testicular cancer and minimal residual tumor masses?
J Clin Oncol 10: 569–573
George DW, Foster RS, Hromas RA, RObertson KA, Vance GH, Ulbright
TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC,
Jung SH, Shen JZ, Finch DE, Kelley MP, Einhorn LH (2003) Update on
late relapse of germ cell tumor: A clinical and molecular analysis. J Clin
Oncol 21: 113–122
Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997)
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann
Oncol 8: 41–47
IGCCCG (1997) International Germ Cell Consensus Classification: a prog-
nostic factor-based staging system for metastatic germ cell cancers. Inter-
national Germ Cell Cancer Collaborative Group. JC l i nO n c o l15: 594–603
Jacobsen KD, Ous S, Waehre H, Trasti H, Stenwig AE, Lien HH, Aass N,
Fossa SD (1999) Ejaculation in testicular cancer patients after post-
chemotherapy retroperitoneal lymph node dissection. Br J Cancer 80:
249–255
Lipphardt ME, Albers P (2004) Late relapse of testicular cancer. World J
Urol 22: 47–54
Michael H, Lucia J, Foster RS, Ulbright TM (2000) The pathology of late
recurrence of testicular germ cell tumors. Am J Surg Pathol 24: 257–273
Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ,
Einhorn LH (1993) Surgical salvage of chemorefractory germ cell tumors.
J Clin Oncol 11: 324–329
Nichols CR (1999) Treatment of recurrent germ cell tumors. Semin Surg
Oncol 17: 268–274
Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD (2003)
Postchemotherapy retroperitoneal surgery remains necessary in patients
with nonseminomatous testicular cancer and minimal residual tumor
masses. J Clin Oncol 21: 3310–3317
Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, Wilsgaard T,
Bremnes RM (2005) Blood pressure and body mass index in long-term
survivors of testicular cancer 28. J Clin Oncol 23: 4980–4990
Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA
(2002) Late recurrence in 1263 men with testicular germ cell tumors.
Multivariate analysis of risk factors and implications for management.
Cancer 95: 520–530
Sobin LH, Wittekind Ch (2002) UICC, International Union against Cancer.
TNM Classification of Malignant Tumours. Wiley-Liss: New York
At late relapse: teratoma/necrosis
At late relapse: viable cancer
Initial: seminoma
Initial: non-seminoma
overall
0 5 10 15 20
Survival-observation time (years)
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
c
a
u
s
e
-
s
p
e
c
i
f
i
c
)
1.0
0.8
0.6
0.4
0.2
0.0
Figure 3 Cumulative survival according to initial and late-relapse
histology.
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Appendix A
Patient # 4 suffered from dysphagia and was, based on primary
histology, considered to have a primary oesophageal cancer, until
expert review of the histological specimen at the NRH led to the
diagnosis of a late relapsing TC.
Patient # 8 had a asymptomatic retroperitoneal relapse, which
was detected by elevated serum HCG during a research-based long-
term survey 10 years after primary treatment (Fossa et al, 2003).
In patient # 14, a routine chest X-ray performed as part of
routine check-up, revealed a new small mass in the left lower lobe.
The histological examination of the thoracotomy specimen
revealed a completely necrotic MGCT metastasis.
Patient # 24, with an initial mediastinal EGGCT, relapsed after 53
4
years with a single 15mm mass in the left lung and normal serum
markers. The initial histological diagnosis of the removed nodule
was adenocarcinoma, with a weak AFP staining. However, review
of the histology performed during the present study revealed that
the mass was a yolk sac tumour.
In patient # 25, a mediastinal tumour and a cyst in the neck had
been removed in 1977, revealing teratoma in both cases. In 1980 he
developed malignant spinal cord compression due to a retro-
peritoneal mass, primarily categorised as ‘unclassifiable carcino-
ma’. After referral to the NRH, the case history, an elevated serum
AFP level and the review of the histology led to the diagnosis of a
recurrent EGGCT.
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